Back
Eli Lilly and Co (LLY)
PharmaceuticalsLLY · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$1255.40
+0.88%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$22.95
ROE
107.5%
Gross margin
82.8%
Debt/Equity
1.39x
Revenue growth
55.5%
Eli Lilly and Co — company intelligence
Earnings surprises
Q2 2026$8.38 vs $6.07 est+38.1%
Q1 2026$8.55 vs $6.73 est+27.0%
Q4 2025$7.54 vs $6.74 est+11.9%
Q3 2025$7.02 vs $5.75 est+22.0%
Analyst consensus · 38 analysts
30 Buy7 Hold1 Sell
Updated Aug 21, 2026
Insider activity · 90 days
8 buys4 sellsnet -9,863 shares
Zakrowski Donald ASell 2,000 · Aug 10, 2026
Hakim AnatSell 5,000 · Aug 7, 2026
Seymour Melissaother 981 · Aug 1, 2026
Recent SEC filings
4 — Insider transaction reportAug 18, 2026
4 — Insider transaction reportAug 18, 2026
4 — Insider transaction reportAug 18, 2026
Latest news
Eli Lilly (NYSE:LLY): A Dividend Quality Pick with Sustainable Growth — ChartMill · 1d ago
Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity — SeekingAlpha · 1d ago
Eli Lilly Makes Foundayo Available To Eligible UK Adults Privately, Seeks NICE Assessment For NHS Use At £100-£120 Pricing — Benzinga · 2d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.